Published by Global Banking & Finance Review®
Posted on April 15, 2025
1 min readLast updated: January 24, 2026
GSK breached ethical standards in Omjjara's prescription info, misleading women on contraceptive use, according to PMCPA.
(Reuters) -British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.
Omjjara is used to treat symptoms such as an enlarged spleen in adults with myelofibrosis - a rare bone marrow blood cancer - and moderate to severe anemia.
The prescribing information provided for the drug misled women using hormonal contraceptives about the necessity for extra precautions to prevent pregnancy, the Prescription Medicines Code of Practice Authority (PMCPA) said.
In response, a GSK spokesperson said: "We take adherence to industry codes and regulations very seriously."
(Reporting by Chandini Monnappa in Bengaluru; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee)
The main topic is GSK's breach of ethical standards in the marketing and prescription information of its drug Omjjara.
Omjjara is used to treat symptoms of myelofibrosis, a rare bone marrow blood cancer, and moderate to severe anemia.
The breach was identified by the Prescription Medicines Code of Practice Authority (PMCPA).
Explore more articles in the Headlines category
